The Honest Guide to MK-677: What Patients and Doctors Actually Say

MK-677 at a glance:

• Drug class: Oral non-peptide ghrelin receptor agonist (development discontinued for FDA approval)
• Route: oral
• Typical frequency: once daily
• Half-life: approximately 4-6 hours

Let's cut through the marketing on MK-677 and look at what the data actually say. MK-677 is a small-molecule, orally active ghrelin receptor agonist that increases GH and IGF-1 levels by mimicking ghrelin's action on the pituitary, and the result for users is: sustained increase in igf-1 and gh levels; modest increases in lean mass and appetite.

What is MK-677?

MK-677 is a small-molecule, orally active ghrelin receptor agonist that increases GH and IGF-1 levels by mimicking ghrelin's action on the pituitary.

There is no single FDA-licensed manufacturer of MK-677 for human therapeutic use. Material in the research and grey markets is supplied by various unregulated sources, which raises real questions about purity and dosing accuracy. MK-677 is not currently approved by the FDA for general human use. Available evidence comes from ongoing clinical trials. We do not endorse self-administration of unapproved compounds.

The drug class oral non-peptide ghrelin receptor agonist (development discontinued for fda approval) works by targeting specific receptor pathways. Here's how that breaks down.

How MK-677 Works in the Body

MK-677 is a small-molecule, orally active ghrelin receptor agonist that increases GH and IGF-1 levels by mimicking ghrelin's action on the pituitary. The receptor target — compound-specific — drives the downstream effects users care about: sustained increase in igf-1 and gh levels; modest increases in lean mass and appetite.

The pharmacokinetics matter for daily use. MK-677 has a half-life of approximately 4-6 hours, which determines how often it is dosed. The standard route of administration is oral, and the typical schedule is once daily.

For more detail on the underlying biology, see our breakdown of how MK-677 works.

Who Uses MK-677?

MK-677 is most relevant for people whose situation maps to its approved indications: none — multiple development programs have stalled.

People who should avoid MK-677 include those with the following:

• allergy to the active ingredient or any excipient
• pregnancy or breastfeeding (per label)
• conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of MK-677 include:

• increased appetite
• edema
• fatigue
• muscle pain

Serious risks — uncommon but worth knowing — include:

• impaired glucose tolerance
• elevated cortisol in some studies
• fluid retention
• potential influence on tumor growth via IGF-1

We have a more detailed breakdown in our MK-677 side-effects guide.

MK-677 vs Alternatives

FDA-approved approaches to GH-axis enhancement remain limited to recombinant GH for confirmed deficiency. If you are weighing MK-677 against another option, our comparison pages include Is MK-677 Safe? An Honest Look at the Side-Effect Profile, MK-677 Outcomes Decoded: Who Responds Best and Why, Why MK-677 Costs So Much (and 5 Ways to Pay Less).

Bottom Line

If you're considering MK-677, the most useful next step is usually a conversation with a clinician who knows the full landscape of options — not just the one they prescribe most often. Phase 2 and 3 data show meaningful benefit, with phase 3 confirmation pending in some cases. If you are considering MK-677, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Is MK-677 Safe? An Honest Look at the Side-Effect Profile
• MK-677 Outcomes Decoded: Who Responds Best and Why
• Why MK-677 Costs So Much (and 5 Ways to Pay Less)
• MK-677 Cycle and Protocol: What Researchers Actually Use
• CJC-1295 101: A Plain-English Guide for 2026
• Ipamorelin Explained: How It Works and Who It's For

Sources

• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.
• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.
• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.